All In Biotech

Drug Trial Radar · NCT05680129

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM

A Phase 3, Multi-center, Open-label, Randomized Study to Evaluate the Efficacy and Safety of XW003 Versus Dulaglutide in Patients With T2DM Inadequately Controlled by Metformin

Last checked: Nov 19, 2026Latest source record: May 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 623 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

623

Actual

Start

Jan 10, 2023

Primary completion

Jul 3, 2024

Study completion Oct 12, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to compare the efficacy and safety of two XW003 doses versus dulaglutide as add-on therapy to metformin in participants with type 2 diabetes mellitus (T2DM)

Conditions

  • T2DM
  • Type 2 Diabetes Mellitus

Interventions

  • Ecnoglutide high dosageDrug

    Administered subcutaneously

  • Ecnoglutide low dosageDrug

    Administered subcutaneously

  • DulaglutideDrug

    Administered subcutaneously

  • MetforminDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in HbA1cTime frame: Baseline, week 32

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ZHONGSHAN Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.